Drug intelligence / Profile preview

compound salvia miltiorrhiza

Development stage
Unknown
Lead developer
Tasly Pharmaceutical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral, Sublingual
01

Overview

Compound salvia miltiorrhiza, commonly known as Compound Danshen Dripping Pills (CDDP) or Fufang Danshen Diwan, is a standardized Traditional Chinese Medicine (TCM) formulation. It primarily consists of extracts from *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and synthetic or natural Borneol. Developed primarily by Tasly Pharmaceuticals, it is widely used for the treatment and prevention of cardiovascular diseases, including chronic stable angina and coronary heart disease. The drug's mechanism of action involves improving coronary microcirculation, inhibiting platelet aggregation, reducing blood viscosity, and providing anti-inflammatory and antioxidant effects. It is formulated as dropping pills (dripping pills) designed for oral or sublingual administration to facilitate rapid absorption. In the United States, a standardized version known as T89 or Dantonic has undergone Phase 3 clinical trials for the treatment of chronic stable angina, making it one of the first TCM products to reach late-stage clinical development under the FDA's botanical drug pathway.

Brand names
Dantonic
Other names
Compound Danshen Dripping PillsCDDPFufang Danshen DiwanCompound Salvia Miltiorrhiza Dropping PillsCompound Salvia Miltiorrhiza Dripping Pills
02

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PDE (Phosphodiesterase family)NOS2 (Nitric Oxide Synthase 2)P2Y12 (Purinergic P2Y12 receptor)PDIA3 (Membrane-associated rapid response steroid-binding receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PDGFRB (Platelet-derived growth factor receptor beta)NOS3 (eNOS)

Beyond the preview

Go deeper on compound salvia miltiorrhiza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound salvia miltiorrhiza.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call